• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genmab A/S - American Depositary Shares (NQ: GMAB )

    21.02 +0.44 (+2.14%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Genmab A/S - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 Next >
    Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
    From Genmab A/S
    Via Business Wire
    NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
    GENMAB A/S -SP ADR (NASDAQ:GMAB)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
    Via Chartmill
    TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
    From Seagen Inc.
    Via Business Wire
    What 13 Analyst Ratings Have To Say About Genmab
    Via Benzinga
    Expert Ratings for Genmab
    Via Benzinga
    Analyst Expectations for Genmab's Future
    Via Benzinga
    While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
    While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable. 
    Via Chartmill
    United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
    Via Benzinga
    Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher
    With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio. 
    Via InvestorPlace
    Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
    From Genmab A/S
    Via Business Wire
    Analyst Expectations for Genmab's Future
    Via Benzinga
    12 Analysts Have This to Say About Genmab
    Via Benzinga
    Where Genmab Stands With Analysts
    Via Benzinga
    EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    From Genmab A/S
    Via Business Wire
    Why Shares of Iovance Biotherapeutics Dropped Thursday
    The biotech stock's lead therapy is looking at some competition. 
    Via The Motley Fool
    AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
    On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients  
    Via Benzinga
    Why Shares of Zai Lab Limited Were Jumping on Tuesday
    Zai Lab's shares benefited from positive clinical trial news. 
    Via The Motley Fool
    Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
    Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on... 
    Via Benzinga
    Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
    From Seagen Inc.
    Via Business Wire
    Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
    From Genmab A/S
    Via Business Wire
    The 3 Most Promising Biotech Stocks to Own Now
    These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential. 
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
    Via Benzinga
    Is AbbVie Still a Good Dividend Stock to Buy?
    Find out if AbbVie can overcome sinking sales of its top-selling product. 
    Via The Motley Fool
    3 Things About Johnson & Johnson Every Smart Investor Knows
    The company has been a strong value stock but faces big changes this year. 
    Via The Motley Fool
    3 Biotech Stocks You Better Be Buying on Each and Every Dip
    Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there. 
    Via InvestorPlace
    Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
    From Genmab A/S
    Via Business Wire
    3 Biotech Stocks That AI is Loving in July
    As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential. 
    Via InvestorPlace
    Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
    In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer. 
    Via The Motley Fool
    Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients
    Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab... 
    Via Benzinga
    Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
    From Genmab
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.